Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706826 | 0.85 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL25366051 | 0.85 | DGAT1 (0.45) | DGAT1NPC1 | |
| SCHEMBL29493833 | 0.85 | DGAT1 (0.45) | DGAT1NPC1 | |
| SCHEMBL31460489 | 0.82 | DGAT1 (0.34) | DGAT1NPC1PDE4D | |
| SCHEMBL15562504 | 0.80 | MAPT (0.34) | NPC1MAPT | |
| SCHEMBL26694764 | 0.80 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL30709985 | 0.80 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL20604807 | 0.79 | HSD17B10 (0.34) | DGAT1NPC1MAPTPDE4D | |
| SCHEMBL32671213 | 0.77 | — | — | |
| SCHEMBL20535503 | 0.77 | DGAT1 (0.36) | DGAT1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4688771-A1 | NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2026-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CTTN, SRC, PTK2 | DGAT1 4421/4885TP53 51/4885NPC1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.